Company: LNAI
Filing Date: 2025-09-29
Form Type: 10-K
Source: 0001731122-25-001316
Chunk: 1166

Company: Lunai Bioworks Inc.
Filing Date: 2025-09-29
Form: 10-K
Item: Item 1
Chunk 1166
---
 party’s intellectual property rights, it
could be required to obtain a license from such third party to continue developing, marketing, selling and distributing our products,
or to cease using the infringing technology. However, we may not be able to obtain any required license on commercially reasonable terms
or at all. Even if we were able to obtain a license, it could be non-exclusive, thereby giving our competitors access to the
same technologies licensed to us. In addition, We could be found liable for monetary damages, including treble damages if it is found
to have willfully infringed a patent and attorneys’ fees if the court finds the case to be exceptional. A finding of infringement,
misappropriation, or other violation could prevent us from commercializing our products or force us to cease some of our operations, which
could materially harm our business. Claims that Renovaro Cube or BioSymetrics has misappropriated the confidential information or trade
secrets of third parties could have a similar negative impact on our business.

40

Even
if resolved in our favor, litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant
expenses and could distract our personnel from their normal responsibilities. Such litigation or proceedings could substantially increase
our operating losses and reduce the resources available for development activities or any future sales, marketing, or distribution activities.
We may not have sufficient financial or other resources to conduct such litigation or proceedings adequately. Some of our competitors
may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources
and more mature and developed intellectual property portfolios. Uncertainties resulting from the initiation and continuation of patent
litigation or other proceedings could have a material adverse effect on our ability to compete in the marketplace.

Renovaro
Cube’s and BioSymetrics’ use of open-source software could subject our proprietary technology to unwanted open-source license
conditions that could negatively impact its business.

A portion
of our technology capabilities incorporates open-source software, and we may incorporate open-source software into
other offerings or products in the future. If an author or other third party that distributed such open-source software to Renovaro
Cube or BioSymetrics were to allege that we had not complied with the conditions of one or more of these licenses, we could be required
to incur significant legal expenses defending against such allegations. Further, the outcome of such litigation may be particularly uncertain
in some cases,